Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Generate BiomedicinesGENB +4.48%6 3-1 Month Momentum % is -8.14% as of Aug. 15, 2026. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review. Among 1,388 Biotechnology companies, Generate Biomedicines ranks worse than 58.65% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-15), Generate Biomedicines's 3-1 Month Momentum % is -8.14%.
The industry rank for Generate Biomedicines's 3-1 Month Momentum % or its related term are showing as below:
GENB's 3-1 Month Momentum % is ranked worse than 58.65% of 1388
companies
in the Biotechnology industry
Industry Median: -8.13
vs GENB: -8.14
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Generate Biomedicines 3-1 Month Momentum % Related Terms
GENB vs ZYME, DMRA, SLBT: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Generate Biomedicines's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Generate Biomedicines 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Generate Biomedicines's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Generate Biomedicines's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generate Biomedicines (GENB) has a 3-1 Month Momentum % of -8.14% as of Aug. 15, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Generate Biomedicines and its competitors. According to the industry distribution chart, Generate Biomedicines ranks #814 out of 1388 companies in the Biotechnology industry, placing it in the top 58.6%.
Is Generate Biomedicines' 3-1 Month Momentum % too high?
Generate Biomedicines' current 3-1 Month Momentum % is -8.14%. Based on the distribution chart, Generate Biomedicines ranks #814 out of 1388 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' 3-1 Month Momentum % compare to ZYME and DMRA?
According to the Biotechnology industry distribution chart, Generate Biomedicines ranks #814 out of 1388 companies for 3-1 Month Momentum %. This places Generate Biomedicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Generate Biomedicines and its competitors. Generate Biomedicines's current 3-1 Month Momentum % is -8.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current 3-1 Month Momentum % of -8.14%. The current 3-1 Month Momentum % is -8.14%. Generate Biomedicines' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current 3-1 Month Momentum % is -8.14% as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score
Get the complete analysis for GENB
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GENB has been successfully added to your 
